Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin discolouration23.03.03.0050.012838%Not Available
Skin disorder23.03.03.0070.003884%Not Available
Skin exfoliation23.03.07.0030.016599%Not Available
Skin fissures23.03.03.0080.005641%Not Available
Skin hyperpigmentation23.05.01.0030.003212%
Skin hypertrophy23.01.04.0020.000246%Not Available
Skin irritation23.03.04.0090.000817%Not Available
Skin lesion23.03.03.010--Not Available
Skin reaction23.03.03.013; 10.01.03.0190.001612%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.002004%
Skin warm23.03.03.0140.000168%Not Available
Sleep disorder19.02.04.001--Not Available
Small intestinal obstruction07.13.06.0010.000839%
Sneezing22.12.03.024--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Splenic infarction01.09.02.004; 24.04.08.0240.000168%Not Available
Stevens-Johnson syndrome12.03.01.014; 11.07.01.005; 10.01.01.045; 23.03.01.0070.000974%
Stomatitis07.05.06.0050.020740%
Stridor22.04.02.0030.000280%
Sudden death08.04.01.003; 02.03.04.0130.000560%
Suffocation feeling22.12.02.0140.000224%Not Available
Superinfection11.01.08.009--Not Available
Supraventricular extrasystoles02.03.03.0110.000392%Not Available
Supraventricular tachycardia02.03.03.012--
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tenderness08.01.08.0050.001063%Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene